Zenas BioPharma (ZBIO) Cash & Current Investments (2023 - 2026)

Zenas BioPharma's Cash & Current Investments history runs 4 years deep, the most recent figure standing at $717.2 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 66.78% year-over-year to $717.2 million in Q1 2026; TTM through Mar 2026 was $717.2 million, a 66.78% increase from a year earlier, with the FY2025 full-year figure at $343.2 million, down 2.16% from the prior year.
• Cash & Current Investments climbed to $717.2 million in Q1 2026 per ZBIO's latest filing, from $343.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $717.2 million in Q1 2026 and bottomed at $37.2 million in Q1 2024.
• The 4-year median for Cash & Current Investments is $343.2 million (2025), against an average of $300.2 million.
• Biggest YoY gain for Cash & Current Investments was 1054.74% in 2025; the steepest drop was 2.16% in 2025.
• Year by year, Cash & Current Investments stood at $56.9 million in 2023, then surged by 516.93% to $350.8 million in 2024, then slipped by 2.16% to $343.2 million in 2025, then soared by 108.98% to $717.2 million in 2026.
• Per Business Quant, the three latest ZBIO Cash & Current Investments figures stand at $717.2 million (Q1 2026), $343.2 million (Q4 2025), and $476.9 million (Q3 2025).